DLA Piper, Nabarro and King & Wood Mallesons (KWM) are among the firms that have advised a clutch of pharmaceutical companies, including GlaxoSmithKline (GSK), as they were fined £45m.
GSK has been fined alongside a raft of other pharmaceutical firms for paying rival drug makers to delay the release of their competing drugs into the UK marketplace between 2001 and 2004.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
